Andrea L Kossler, MD
Ophthalmology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kossler’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A121372 · Current
Licensed to practise in California · since 2012 · expires 2027-10-31 · Georgetown University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$133,838
Medicare paid this office $133,838 for 319 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 184 | $16,331 | $83 |
| Correction of widely-opened upper eyelid | 12 | $6,464 | $539 |
| Long return visit (40+ min) | 38 | $6,171 | $121 |
| Reconstruction of eyelid margin | 19 | $6,162 | $324 |
| New patient visit (45+ min) | 43 | $4,954 | $115 |
See all 12 services
| Return visit (30+ min) | 184 | $16,331 | $83 |
| Correction of widely-opened upper eyelid | 12 | $6,464 | $539 |
| Long return visit (40+ min) | 38 | $6,171 | $121 |
| Reconstruction of eyelid margin | 19 | $6,162 | $324 |
| New patient visit (45+ min) | 43 | $4,954 | $115 |
| Exam of visual field with extended testing | 123 | $3,277 | $24 |
| New patient visit (60+ min) | 15 | $2,273 | $152 |
| Short return visit (20+ min) | 37 | $2,184 | $55 |
| Removal of growth of eyelid | 14 | $1,790 | $128 |
| Temporary closure of eyelids by suture | 17 | $1,003 | $50 |
| Photography of content of eyes | 217 | $605 | $3 |
| Imaging of optic nerve | 26 | $596 | $20 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 20 | More than 74% of doctors who do this |
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
319 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 12% · Women 67% · Also on Medicaid 19% · Health risk score 1.07. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 64% · Diabetes 24% · Coronary heart disease 24% · Cancer 18% · Depression 18% · Atrial fibrillation 16% · Chronic kidney disease 13% · Heart failure 12% · COPD 8% · Stroke 8%.
The office billed $2,325,983, Medicare allowed $171,858 and paid $133,838; for 1,050 services of 87 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 319 | 1,050 | 74 | 1.07 | $2,325,983 | $133,838 |
| 2023 | 302 | 1,064 | 75 | 1.12 | $2,378,600 | $155,551 |
| 2022 | 348 | 1,048 | 73 | 1.08 | $1,902,283 | $131,043 |
| 2021 | 287 | 922 | 74 | 1.16 | $1,732,552 | $104,180 |
| 2020 | 267 | 882 | 73 | 1.35 | $2,124,082 | $129,921 |
| 2019 | 355 | 1,261 | 74 | 1.34 | $2,715,981 | $180,535 |
| 2018 | 333 | 1,287 | 72 | 1.40 | $2,895,731 | $189,474 |
| 2017 | 338 | 1,280 | 73 | 1.35 | $1,893,566 | $165,351 |
| 2016 | 319 | 1,018 | 73 | 1.40 | $1,559,512 | $152,736 |
| 2015 | 351 | 1,128 | 74 | 1.24 | $1,395,649 | $134,702 |
| 2014 | 313 | 1,149 | 74 | 1.30 | $1,644,407 | $160,355 |
| 2013 | 287 | 1,261 | 74 | 1.35 | $1,927,937 | $188,603 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Return visit (30+ min) | 145 | $14,404 | $89 |
| Correction of widely-opened upper eyelid | 17 | $9,759 | $465 |
| Reconstruction of eyelid margin | 22 | $8,992 | $375 |
| Long return visit (40+ min) | 39 | $6,662 | $119 |
| New patient visit (45+ min) | 48 | $5,715 | $119 |
| Removal of growth of eyelid | 19 | $3,908 | $118 |
| Short return visit (20+ min) | 52 | $3,149 | $56 |
| Exam of visual field with extended testing | 104 | $2,988 | $25 |
| New patient visit (60+ min) | 14 | $2,338 | $167 |
| Probing of nasal tear duct | 14 | $2,199 | $147 |
| Temporary closure of eyelids by suture | 22 | $1,204 | $50 |
| Established patient complete exam of visual system | 16 | $1,091 | $68 |
| Photography of content of eyes | 214 | $649 | $3 |
| Imaging of optic nerve | 24 | $573 | $20 |
2022: 15 services
| Return visit (30+ min) | 144 | $12,743 | $84 |
| Long return visit (40+ min) | 80 | $12,448 | $122 |
| Reconstruction of eyelid margin | 17 | $6,426 | $357 |
| Correction of widely-opened upper eyelid | 11 | $5,503 | $459 |
| New patient visit (45+ min) | 47 | $5,280 | $112 |
| Exam of visual field with extended testing | 119 | $3,043 | $23 |
| New patient visit (60+ min) | 19 | $3,042 | $160 |
| Probing of nasal tear duct | 12 | $1,857 | $155 |
| Short return visit (20+ min) | 28 | $1,613 | $56 |
| Removal of growth of eyelid | 11 | $1,354 | $104 |
| Established patient complete exam of visual system | 14 | $1,021 | $73 |
| Imaging of optic nerve | 36 | $910 | $20 |
| Photography of content of eyes | 238 | $709 | $3 |
| New patient visit (30+ min) | 12 | $698 | $58 |
| Temporary closure of eyelids by suture | 12 | $570 | $48 |
2021: 11 services
| Return visit (30+ min) | 105 | $10,105 | $82 |
| Reconstruction of eyelid margin | 22 | $7,193 | $300 |
| New patient visit (30+ min) | 51 | $3,765 | $74 |
| New patient visit (45+ min) | 31 | $3,696 | $119 |
| Long return visit (40+ min) | 23 | $3,542 | $122 |
| Removal of growth of eyelid | 22 | $3,462 | $105 |
| Probing of nasal tear duct | 19 | $2,909 | $153 |
| Exam of visual field with extended testing | 95 | $2,663 | $25 |
| Short return visit (20+ min) | 41 | $2,191 | $52 |
| Imaging of optic nerve | 29 | $632 | $20 |
| Photography of content of eyes | 201 | $600 | $3 |
2020: 15 services
| Removal of excessive skin and fat of upper eyelid | 19 | $14,973 | $749 |
| Return visit (30+ min) | 106 | $8,384 | $67 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 14 | $7,622 | $508 |
| Reconstruction of eyelid margin | 13 | $4,927 | $379 |
| Probing of nasal tear duct | 19 | $3,347 | $159 |
| New patient visit (30+ min) | 46 | $2,938 | $64 |
| Short return visit (20+ min) | 61 | $2,765 | $42 |
| Tightening of tendon of outer edge of lower eyelid | 11 | $2,733 | $248 |
| Removal of growth of eyelid | 18 | $2,413 | $105 |
| Exam of visual field with extended testing | 66 | $1,869 | $24 |
| Long return visit (40+ min) | 14 | $1,732 | $96 |
| Established patient complete exam of visual system | 22 | $1,574 | $72 |
| New patient visit (45+ min) | 12 | $1,322 | $110 |
| Imaging of optic nerve | 19 | $512 | $20 |
| Photography of content of eyes | 163 | $493 | $3 |
2019: 17 services
| Removal of excessive skin and fat of upper eyelid | 29 | $21,382 | $737 |
| Return visit (30+ min) | 129 | $9,282 | $66 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 12 | $6,989 | $582 |
| Reconstruction of eyelid margin | 19 | $5,860 | $293 |
| Probing of nasal tear duct | 29 | $5,100 | $150 |
| New patient visit (30+ min) | 75 | $4,600 | $61 |
| Short return visit (20+ min) | 83 | $4,084 | $42 |
| Removal of growth of eyelid | 23 | $2,998 | $100 |
| Established patient complete exam of visual system | 36 | $2,900 | $74 |
| Exam of visual field with extended testing | 95 | $2,274 | $23 |
| New patient visit (45+ min) | 15 | $1,727 | $115 |
| Probing of nasal tear duct with insertion of tube or stent | 12 | $1,473 | $123 |
| Long return visit (40+ min) | 12 | $1,049 | $87 |
| Temporary closure of eyelids by suture | 14 | $792 | $53 |
| Photography of content of eyes | 242 | $715 | $3 |
| Removal of eyelashes using forceps | 16 | $699 | $35 |
| Imaging of optic nerve | 27 | $527 | $19 |
2018: 19 services
| Removal of excessive skin and fat of upper eyelid | 18 | $12,556 | $698 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 20 | $10,487 | $524 |
| Return visit (30+ min) | 133 | $10,172 | $66 |
| Reconstruction of eyelid margin | 18 | $6,575 | $365 |
| Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.0 sq cm or less | 17 | $6,231 | $346 |
| Extensive repair of turning-outward eyelid defect | 19 | $5,620 | $281 |
| Probing of nasal tear duct | 33 | $5,472 | $133 |
| Established patient complete exam of visual system | 53 | $3,935 | $66 |
| New patient visit (30+ min) | 58 | $3,309 | $57 |
| New patient visit (45+ min) | 28 | $2,956 | $106 |
| Long return visit (40+ min) | 29 | $2,585 | $89 |
| Removal of growth of eyelid | 16 | $2,289 | $127 |
| Short return visit (20+ min) | 46 | $2,279 | $39 |
| Exam of visual field with extended testing | 83 | $2,046 | $23 |
| Probing of nasal tear duct with insertion of tube or stent | 16 | $1,940 | $121 |
| Temporary closure of eyelids by suture | 21 | $1,162 | $51 |
| Removal of eyelashes using forceps | 20 | $1,102 | $42 |
| Photography of content of eyes | 209 | $571 | $2 |
| Imaging of optic nerve | 23 | $406 | $18 |
2017: 20 services
| Return visit (30+ min) | 148 | $11,796 | $67 |
| Removal of excessive skin and fat of upper eyelid | 15 | $11,344 | $756 |
| Reconstruction of eyelid margin | 24 | $10,149 | $390 |
| Probing of nasal tear duct | 56 | $9,232 | $149 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 14 | $7,701 | $550 |
| Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.0 sq cm or less | 15 | $7,248 | $345 |
| Long return visit (40+ min) | 54 | $5,651 | $97 |
| New patient visit (45+ min) | 42 | $4,667 | $111 |
| Extensive repair of turning-outward eyelid defect | 13 | $4,595 | $353 |
| Short return visit (20+ min) | 73 | $4,223 | $44 |
| New patient visit (30+ min) | 58 | $3,802 | $66 |
| Removal of growth of eyelid | 24 | $3,370 | $130 |
| Probing of nasal tear duct with insertion of tube or stent | 13 | $2,102 | $150 |
| Exam of visual field with extended testing | 74 | $2,001 | $24 |
| Established patient complete exam of visual system | 25 | $1,927 | $69 |
| Removal of eyelashes using forceps | 13 | $1,097 | $50 |
| Temporary closure of eyelids by suture | 16 | $900 | $53 |
| Injection into skin growth, 1-7 growths | 13 | $626 | $26 |
| Photography of content of eyes | 191 | $567 | $3 |
| Imaging of optic nerve | 26 | $527 | $20 |
2016: 14 services
| Removal of excessive skin and fat of upper eyelid | 20 | $13,997 | $700 |
| Return visit (30+ min) | 128 | $9,083 | $62 |
| Probing of nasal tear duct | 31 | $4,363 | $132 |
| Reconstruction of eyelid margin | 11 | $3,632 | $330 |
| Established patient complete exam of visual system | 48 | $3,310 | $66 |
| New patient visit (45+ min) | 31 | $3,253 | $105 |
| Long return visit (40+ min) | 29 | $2,940 | $98 |
| Short return visit (20+ min) | 65 | $2,641 | $37 |
| Removal of growth of eyelid | 17 | $2,444 | $116 |
| Exam of visual field with extended testing | 89 | $2,201 | $23 |
| New patient visit (30+ min) | 33 | $1,755 | $53 |
| Removal of eyelashes using forceps | 13 | $585 | $45 |
| Imaging of optic nerve | 16 | $386 | $24 |
| Photography of content of eyes | 144 | $385 | $3 |
2015: 16 services
| Return visit (30+ min) | 149 | $11,913 | $67 |
| Removal of excessive skin and fat of upper eyelid | 17 | $8,703 | $512 |
| Probing of nasal tear duct | 43 | $6,256 | $123 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 14 | $5,653 | $404 |
| Short return visit (20+ min) | 104 | $5,623 | $43 |
| New patient visit (30+ min) | 68 | $4,500 | $66 |
| Reconstruction of eyelid margin | 15 | $4,227 | $282 |
| Removal of growth of eyelid | 24 | $3,502 | $125 |
| Probing of nasal tear duct with insertion of tube or stent | 20 | $3,224 | $154 |
| Extensive repair of turning-outward eyelid defect | 11 | $2,886 | $262 |
| New patient visit (45+ min) | 25 | $2,698 | $108 |
| Exam of visual field with extended testing | 75 | $2,240 | $25 |
| Long return visit (40+ min) | 12 | $1,179 | $98 |
| Removal of eyelashes using forceps | 16 | $742 | $46 |
| Photography of content of eyes | 140 | $415 | $3 |
| Imaging of optic nerve | 14 | $386 | $26 |
2014: 19 services
| Removal of excessive skin and fat of upper eyelid | 18 | $9,225 | $512 |
| Repair of tendon of upper eyelid | 15 | $8,181 | $511 |
| Short return visit (20+ min) | 154 | $7,752 | $41 |
| Reconstruction of eyelid margin | 19 | $6,312 | $332 |
| Return visit (30+ min) | 84 | $5,851 | $65 |
| Probing of nasal tear duct | 43 | $5,482 | $117 |
| Removal of growth of eyelid | 29 | $4,482 | $115 |
| New patient visit (30+ min) | 67 | $3,983 | $59 |
| Extensive repair of turning-outward eyelid defect | 14 | $3,943 | $246 |
| New patient visit (45+ min) | 26 | $2,497 | $96 |
| Suture repair of turning-outward upper or lower eyelid defect | 15 | $2,395 | $160 |
| Established patient problem focused exam of visual system | 44 | $2,088 | $44 |
| Probing of nasal tear duct with insertion of tube or stent | 13 | $1,619 | $125 |
| Exam of visual field with extended testing | 61 | $1,606 | $24 |
| Removal of eyelashes using forceps | 24 | $1,299 | $43 |
| Temporary closure of eyelids by suture | 17 | $1,262 | $60 |
| Established patient complete exam of visual system | 11 | $790 | $72 |
| Photography of content of eyes | 125 | $339 | $2 |
| Imaging of optic nerve | 11 | $288 | $26 |
2013: 24 services
| Return visit (30+ min) | 147 | $11,694 | $65 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 16 | $10,774 | $539 |
| Exploration of cavity behind eye | 11 | $10,709 | $892 |
| Extensive repair of turning-outward eyelid defect | 34 | $10,644 | $280 |
| Removal of excessive skin and fat of upper eyelid | 16 | $8,715 | $513 |
| Probing of nasal tear duct | 52 | $6,628 | $110 |
| Short return visit (20+ min) | 106 | $5,879 | $44 |
| Plastic repair of tear duct | 11 | $5,121 | $466 |
| Reconstruction of eyelid margin | 14 | $4,858 | $304 |
| New patient visit (45+ min) | 39 | $4,132 | $106 |
| Removal of up to 1/4 of eyelid margin and repair of eyelid | 13 | $4,052 | $312 |
| Probing of nasal tear duct with insertion of tube or stent | 26 | $3,624 | $139 |
| New patient visit (30+ min) | 53 | $3,463 | $65 |
| Repair of brow paralysis | 11 | $3,414 | $284 |
| Removal of eyelashes using forceps | 30 | $2,797 | $47 |
| Long return visit (40+ min) | 27 | $2,155 | $80 |
| Exam of visual field with extended testing | 53 | $1,663 | $26 |
| Established patient complete exam of visual system | 24 | $1,626 | $68 |
| Removal of growth of eyelid | 13 | $1,490 | $99 |
| Temporary closure of eyelids by suture | 17 | $931 | $47 |
| Snip incision of tear duct at inner corner of eye | 11 | $657 | $55 |
| Established patient problem focused exam of visual system | 12 | $573 | $48 |
| Imaging of retina | 13 | $369 | $26 |
| Photography of content of eyes | 90 | $264 | $3 |
Medicaid work
$644 in 2024
Medicaid paid $644 for 25 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 25 | $644 |
| 2024 | 25 | 1 | 13 | $644 |
| 2023 | 26 | 1 | 14 | $829 |
| 2022 | 27 | 1 | 15 | $1,095 |
| 2021 | 14 | 1 | 14 | $366 |
| 2018 | 26 | 1 | 13 | $766 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 26 | $829 |
2022
| Return visit (30+ min) | 27 | $1,095 |
2021
| Return visit (30+ min) | 14 | $366 |
2018
| Return visit (30+ min) | 26 | $766 |
Drugs they prescribed that Part D paid
$500
Pharmacies billed $500 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
29 generic and 11 brand-name prescriptions · $500 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Neomycin-Polymyxin-Dexameth | 11 | $202 | $16 |
Year by year
| 2024 | 40 | 27 | None | 28% | $500 |
| 2023 | 159 | 70 | 9% (15) | 26% | $2,297 |
| 2022 | 93 | 49 | None | 37% | $363,411 |
| 2021 | 78 | 46 | None | 31% | $2,689 |
| 2020 | 91 | 48 | None | 35% | $4,105 |
| 2019 | 124 | 75 | None | 40% | $14,014 |
| 2018 | 137 | 75 | None | 53% | $11,433 |
| 2017 | 143 | 77 | None | 36% | $6,690 |
| 2016 | 124 | 65 | None | 40% | $6,722 |
| 2015 | 139 | 80 | 10% (14) | 35% | $5,342 |
| 2014 | 178 | 95 | None | 29% | $7,050 |
| 2013 | 137 | 65 | 8% (11) | 26% | $5,809 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Neomycin-Polymyxin-Dexameth | 74 | $1,118 | $15 |
| Methylprednisolone | 15 | $148 | $10 |
| Ondansetron Odt | 17 | $120 | $7 |
| Hydrocodone-Acetaminophen | 13 | $102 | $8 |
2022: 2 drugs
| Neomycin-Polymyxin-Dexameth | 40 | $551 | $14 |
| Erythromycin | 12 | $106 | $9 |
2021: 1 drug
| Neomycin-Polymyxin-Dexameth | 25 | $384 | $15 |
2020: 1 drug
| Neomycin-Polymyxin-Dexameth | 41 | $716 | $17 |
2019: 2 drugs
| Neomycin-Polymyxin-Dexameth | 46 | $728 | $16 |
| Erythromycin | 18 | $219 | $12 |
2018: 3 drugs
| Neomycin-Polymyxin-Dexameth | 51 | $767 | $15 |
| Prednisolone Acetate | 14 | $672 | $48 |
| Olopatadine | 14 | $520 | $37 |
2017: 4 drugs
| Fluorometholone | 12 | $1,056 | $88 |
| Olopatadine | 12 | $981 | $82 |
| Neomycin-Polymyxin-Dexameth | 47 | $728 | $15 |
| Erythromycin | 18 | $189 | $11 |
2016: 3 drugs
| Neomycin-Polymyxin-Dexameth | 39 | $731 | $19 |
| Prednisolone Acetate | 13 | $543 | $42 |
| Erythromycin | 14 | $132 | $9 |
2015: 4 drugs
| Neomycin-Polymyxin-Dexameth | 40 | $630 | $16 |
| Prednisolone Acetate | 11 | $519 | $47 |
| Bacitracin-Polymyxin | 17 | $353 | $21 |
| Erythromycin | 14 | $179 | $13 |
2014: 2 drugs
| Neomycin-Polymyxin-Dexameth | 60 | $951 | $16 |
| Bacitracin-Polymyxin | 35 | $715 | $20 |
2013: 3 drugs
| Bromfenac | 11 | $1,208 | $110 |
| Neomycin-Polymyxin-Dexameth | 41 | $721 | $18 |
| Bacitracin-Polymyxin | 17 | $381 | $22 |
Money from drug and device companies
$7,775 in 2025
| 2025 | 11 | 22 | $4,266 | $7,775 |
| 2024 | 5 | 31 | $15,780 | $19,060 |
| 2023 | 8 | 20 | $25,214 | $25,995 |
| 2022 | 3 | 9 | $9,950 | $10,528 |
| 2021 | 2 | 3 | $3,000 | $3,101 |
| 2020 | 2 | 20 | $20,515 | $22,145 |
| 2019 | 6 | 10 | $2,130 | $2,772 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Tepezza | $3,494 | 8 payments
|
| Axogen | None | $1,500 | 1 payment
|
| Genentech | Actemra | $1,150 | 1 payment
|
| Argenx US | Vyvgart | $766 | 3 payments
|
| Biotissue Holdings | None | $213 | 2 payments
|
| Glaukos | Photrexa Viscous and Photrexa | $177 | 1 payment
|
See all 22 published payments
| Argenx US | Consulting · 2025-12-10 | Vyvgart | $431 |
| Axogen | Consulting · 2025-11-25 | None | $1,500 |
| Amgen | Consulting · 2025-11-18 | Tepezza | $850 |
| Amgen | Meals · 2025-10-28 | None | $95 |
| Amgen | Travel · 2025-10-27 | None | $269 |
| Amgen | Travel · 2025-10-27 | None | $760 |
| Amgen | Travel · 2025-10-27 | None | $257 |
| Genentech | Consulting · 2025-10-20 | Actemra | $1,150 |
| ANI Pharmaceuticals | Meals · 2025-10-16 | Purified Cortrophin Gel | $75 |
| Amgen | Meals · 2025-09-26 | Tepezza | $66 |
| Amgen | Travel · 2025-09-25 | Tepezza | $963 |
| Amgen | Travel · 2025-09-25 | Tepezza | $234 |
| Stryker | Meals · 2025-08-15 | Na | $89 |
| Biotissue Holdings | Meals · 2025-08-12 | None | $38 |
| Biotissue Holdings | Meals · 2025-08-12 | None | $175 |
| Abbvie | Meals · 2025-08-09 | Ozurdex | $94 |
| Tarsus Pharmaceuticals | Meals · 2025-08-08 | Xdemvy | $103 |
| ANI Pharmaceuticals | Meals · 2025-08-08 | Purified Cortrophin Gel | $17 |
| Bausch & Lomb Americas | Meals · 2025-08-07 | None | $96 |
| Glaukos | Meals · 2025-03-11 | Photrexa Viscous and Photrexa | $177 |
| Argenx US | Consulting · 2025-01-15 | Vyvgart Hytrulo | $35 |
| Argenx US | Consulting · 2025-01-15 | Vyvgart Hytrulo | $300 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $19,060
| Amgen | Tepezza | $15,241 | 7 payments
|
| Abbvie | Ozurdex | $2,188 | 17 payments
|
| Janssen Research & Development | None | $1,275 | 1 payment
|
| Stryker | Core | $183 | 3 payments
|
| Tarsus Pharmaceuticals | Xdemvy | $173 | 3 payments
|
2023: $25,995
| Horizon Therapeutics plc | Tepezza | $15,424 | 11 payments
|
| Genentech | Enspryng | $4,888 | 2 payments
|
| H. Lundbeck A S | Vyepti | $2,800 | 1 payment
|
| Argenx US | Vyvgart | $2,346 | 2 payments
|
| Axogen | Avance Nerve Graft | $175 | 1 payment
|
| Bausch & Lomb Americas | None | $140 | 1 payment
|
| Stryker | Na | $123 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $100 | 1 payment
|
2022: $10,528
| Horizon Therapeutics plc | Tepezza | $10,270 | 6 payments
|
| Stryker | Xpress Ent Dilation System | $153 | 1 payment
|
| KLS-Martin L.P. | None | $105 | 2 payments
|
2021: $3,101
| Horizon Therapeutics plc | Tepezza | $3,007 | 2 payments
|
| Stryker | Na | $94 | 1 payment
|
2020: $22,145
| Horizon Therapeutics plc | Tepezza | $22,125 | 19 payments
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
2019: $2,772
| Horizon Therapeutics plc | None | $2,157 | 3 payments
|
| Mallinckrodt Enterprises | Acthar | $358 | 3 payments
|
| Galderma Laboratories L.P. | None | $133 | 1 payment
|
| Stryker | Universal Upper-Face | $81 | 1 payment
|
| Axogen | Axoguard Nerve Protector | $30 | 1 payment
|
| Osteomed | Cmf-Cfx | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Amgen Inc. · P4 Ted Pmr · 2024 | Their institution | $923,377 |
| Horizon Therapeutics plc · A Phase 3b/4, Double-Masked, Randomized, International, Parallel-Assignment, Multicenter Trial in Patients With Thyroid Eye Disease To Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab · 2023 | Their institution | $136,922 |
| Amgen Inc. · A Randomized, Open-Label, International, Parallel-Assignment, Multicenter Trial in Patients With Thyroid Eye Disease To Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab · 2024 | Their institution | $59,099 |
| Amgen Inc. · A Phase 3b/4, Double-Masked, Randomized, International, Parallel-Assignment, Multicenter Trial in Patients With Thyroid Eye Disease To Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab · 2025 | Their institution | $55,170 |
| Horizon Therapeutics plc · A Phase 3b/4, Double-Masked, Randomized, International, Parallel-Assignment, Multicenter Trial in Patients With Thyroid Eye Disease To Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab · 2022 | Their institution | $5,063 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1285884106
- Licence
- CA A121372, FL 11351California A121372: Current · expires 2027-10-31
- Trained
- Georgetown University School of Medicine, 2006
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0200X (207WX0200X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1804 Embarcadero Rd, Suite 100, Palo Alto, CA, 94303
- NPI first listed
- 2008-09-28
- NPI last updated
- 2024-04-04
- NPI record certified
- 2024-04-04
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2452 Watson Ct, Palo Alto, CA, 94303